Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and ...
In " Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels continue ...
The Scottish Medicines Consortium approves new cancer drugs Tagrisso (osimertinib) and Calquence (acalabrutinib) for NHS ...
Time-limited acalabrutinib plus venetoclax improves outcomes vs chemoimmunotherapy, offering the first FDA-approved all-oral fixed-duration CLL option, explains Adam Kittai, MD.
The Scottish Medicines Consortium approves new cancer drugs Tagrisso (osimertinib) and Calquence (acalabrutinib) for NHS Scotland lung and ...
Ben Riley had started a newsletter to help people make better decisions about when and how to use generative AI – but seemed ...
A recent narrative review looks at the most effective and emerging options for diagnosing and treating basal cell carcinoma.
Regeneron and Telix announced a strategic radiopharma collaboration worth up to $4.3 billion. Daiichi Sankyo entered a $1.55 ...
Eli Lilly’s Jaypirca (pirtobrutinib) has succeeded in its fourth Phase III trial in chronic lymphocytic leukaemia (CLL). The ...
The BRUIN CLL-322 trial evaluated the safety and efficacy of pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL patients.
As new therapies emerge, particularly for non-muscle invasive disease, clinicians and patients are faced with increasingly ...
Snake oil: a product that promises everything and delivers nothing. Are red light therapy and saunas in this class of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results